SWMP
TEVA icon

Signature Wealth Management Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Signature Wealth Management Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,556
Closed -$152K – 114
2021
Q3 		$152K Sell
15,556
-12,155
-44% -$114K 0.14% 105
2021
Q2 		$274K Sell
27,711
-12,491
-31% -$132K 0.25% 88
2021
Q1 		$464K Buy
40,202
+22,811
+131% +$262K 0.45% 59
2020
Q4 		$168K Buy
+17,391
New +$167K 0.17% 91

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Signature Wealth Management Partners's TEVA Position: Q4 2021 in Review

Signature Wealth Management Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2021, closing a stake of 15,556 shares — an estimated $152K sold.

Signature Wealth Management Partners first reported a position in TEVA in Q4 2020 and held it in 4 quarters. The position peaked at $464K in Q1 2021. 450 funds tracked by Wall St. Rank hold TEVA as of Q4 2021.

  • Signature Wealth Management Partners reported no remaining Teva Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Signature Wealth Management Partners sold 15,556 Teva Pharmaceuticals shares in Q4 2021, an estimated $152K.
  • Signature Wealth Management Partners first reported a position in Teva Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Signature Wealth Management Partners's Teva Pharmaceuticals position peaked at $464K in Q1 2021.
  • 450 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2021.

Based on Signature Wealth Management Partners's 13F filing for Q4 2021, filed 19 Jan 2022.